Şevin Turcan (Sevin Turcan)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 14

Top Topics

Helicobacter Pylori

Single Molecule

Top Venues

Acta neuropathologica communications

Advanced healthcare materials

This page only lists publications with an associated author ORCID identifier.

Publications

Jong-Whi Park, Omer Kilic, Minh Deo, Kevin Jimenez-Cowell, Engin Demirdizen, Hyunggee Kim, Şevin Turcan
CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. Acta neuropathologica communications 11 (1) (2023)
Jong-Whi Park, Omer Kilic, Minh Deo, Kevin Jimenez-Cowell, Engin Demirdizen, Hyunggee Kim, Şevin Turcan
CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. Acta neuropathologica communications 11 (1) (2023)
Haijun Cui, Xueyuan Sun, Marcel Schilling, Christel Herold-Mende, Markus Reischl, Pavel A Levkin, Anna A Popova, Şevin Turcan
Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip. Advanced healthcare materials (2023)
Jong-Whi Park, Omer Kilic, Minh Deo, Kevin Jimenez-Cowell, Engin Demirdizen, Hyunggee Kim, Şevin Turcan
CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. Acta neuropathologica communications 11 (1) (2023)
Margaux Fresnais, Ina Jung, Uli B Klein, Aubry K Miller, Şevin Turcan, Walter Emil Haefeli, Juergen Burhenne, Rémi Longuespée
Important Requirements for Desorption/Ionization Mass Spectrometric Measurements of Temozolomide-Induced 2'-Deoxyguanosine Methylations in DNA. Cancers 15 (3) (2023)
Margaux Fresnais, Ina Jung, Uli B Klein, Aubry K Miller, Şevin Turcan, Walter Emil Haefeli, Juergen Burhenne, Rémi Longuespée
Important Requirements for Desorption/Ionization Mass Spectrometric Measurements of Temozolomide-Induced 2'-Deoxyguanosine Methylations in DNA. Cancers 15 (3) (2023)
Haijun Cui, Xueyuan Sun, Marcel Schilling, Christel Herold-Mende, Markus Reischl, Pavel A Levkin, Anna A Popova, Şevin Turcan
Repurposing FDA-Approved Drugs for Temozolomide-resistant IDH1 Mutant Glioma using High-Throughput Miniaturized Screening on Droplet Microarray Chip. Advanced healthcare materials (2023)
Jong-Whi Park, Omer Kilic, Minh Deo, Kevin Jimenez-Cowell, Engin Demirdizen, Hyunggee Kim, Şevin Turcan
CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. Acta neuropathologica communications 11 (1) (2023)
Anna Schönrock, Elisa Heinzelmann, Bianca Steffl, Engin Demirdizen, Ashwin Narayanan, Damir Krunic, Marion Bähr, Jong-Whi Park, Claudia Schmidt, Koray Özduman, M Necmettin Pamir, Wolfgang Wick, Felix Bestvater, Dieter Weichenhan, Christoph Plass, Julian Taranda, Moritz Mall, Şevin Turcan
MEOX2 homeobox gene promotes growth of malignant gliomas. Neuro-oncology 24 (11) (2022)
Yingying Liang, Şevin Turcan
Epigenetic Drugs and Their Immune Modulating Potential in Cancers. Biomedicines 10 (2) (2022)
Julian Taranda, Şevin Turcan
3D Whole-Brain Imaging Approaches to Study Brain Tumors. Cancers 13 (8) (2021)
Xueyuan Sun, Şevin Turcan
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. Cells 10 (5) (2021)
Ruslan Al-Ali, Katharina Bauer, Jong-Whi Park, Ruba Al Abdulla, Valentina Fermi, Andreas von Deimling, Christel Herold-Mende, Jan-Philipp Mallm, Carl Herrmann, Wolfgang Wick, Şevin Turcan
Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. Acta neuropathologica communications 7 (1) (2019)
Jong-Whi Park, Şevin Turcan
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas. Cancers 11 (10) (2019)